Palmarplantar erythrodysesthesia in the patients with oncological pathology treated with multikinase inhibitors and the method for its correction
- Authors: Kruglova L.S1, Shatokhina E.A.2,1, Kotenko K.V2
-
Affiliations:
- State budgetary healthcare institution of Moscow “Moscow scientific-practical center of dermatovenereology and cosmetology”, Moscow Healthcare Department
- Federal state budgetary institution of additional professional education “Central State Medical Academy”, Presidential Administration of the President of Russian Federation
- Issue: Vol 15, No 6 (2016)
- Pages: 314-317
- Section: Articles
- URL: https://journal-vniispk.ru/1681-3456/article/view/41627
- DOI: https://doi.org/10.18821/1681-3456-2016-15-6-314-317
- ID: 41627
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
L. S Kruglova
State budgetary healthcare institution of Moscow “Moscow scientific-practical center of dermatovenereology and cosmetology”, Moscow Healthcare Department123104, Moscow, Russian Federation
Evgeniya Afanas’evna Shatokhina
Federal state budgetary institution of additional professional education “Central State Medical Academy”, Presidential Administration of the President of Russian Federation; State budgetary healthcare institution of Moscow “Moscow scientific-practical center of dermatovenereology and cosmetology”, Moscow Healthcare Department
Email: e.a.shatokhina@gmail.com
candidate med. sci., associated professor for the Federal state budgetary institution of additional professional education “Central State Medical Academy”, Presidential Administration of the Russian Federation 121359, Moscow, Russian Federation
K. V Kotenko
Federal state budgetary institution of additional professional education “Central State Medical Academy”, Presidential Administration of the President of Russian Federation121359, Moscow, Russian Federation
References
- Johnston J.B., Navaratnam S., Pitz M.W. et al. Targeting the EGFR pathway for cancer therapy. Curr. Med. Chem. 2006; 13: 3483-92.
- Heidary N., Naik H., Burgin S. Chemotherapeutic agents and the skin: an update. J. Am. Acad. Dermatol. 2008; 58: 545-70.
- Chen H.X., Cleck J.N. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 2009; 6(8): 465-77.
- Chu D., Fillos T., Wu S. Risk of handfoot skin reaction with sorafenib: A systematic review and meta-analysis. Acta Oncol. 2008; 47: 176-86.
- Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat. Rev. 2005; 31(6): 456-73.
- Lacouture M.E., Reilly L.M., Gerami P., Guitart J. Hand-foot skin reaction in cancer patients treated with the multikinase inhibitor sorafenib and sunitinib. Ann. Oncol. 2008; 19: 1955-61.
- Robert C., Mateus C., Spatz A., Wechsler J., Escudier B. Dermatologic symptoms associated with the multikinaseinhibitor sorafenib. J. Am. Acad. Dermatol. 2009; 60: 299-305.
- Degen A., Alter M., Schenck F., Satzger I., Völker R., Kapp A., Gutzmer A. Hand-Foot Syndrome in cancer patients: concepts, assessment and management of symptoms. JDDG. 2010; 8: 652-61.
- Jayastu S., Anup J.D., Abhijeet G., Leni G., Auro V. Sorafenib induced hand foot skin rash in FLT3 ITD mutated acute myeloid leukemia-A. Mediterr. J. Hematol. Infect. Dis. 2014; 6(1): e2014016.
- Lacouture M.E., Wu S., Robert C. et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008; 13: 1001-11.
- Robert C., Soria J.C., Spatz A. et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005; 6: 491-500.
- Gurer H., Ozgunes H., Oztezcan S. et al. Antioxidant role of alpha-lipoic acid in lead toxicity. Free Radic. Biol. Med. 1999; 27(1-2): 75-81.
Supplementary files
